We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Boston Scientific (BSX) Stock Sinks As Market Gains: What You Should Know
Read MoreHide Full Article
Boston Scientific (BSX - Free Report) closed at $42.60 in the latest trading session, marking a -1.46% move from the prior day. The stock fell short of the S&P 500, which registered a gain of 0.73% for the day. Elsewhere, the Dow gained 0.49%, while the tech-heavy Nasdaq added 1.19%.
Coming into today, shares of the medical device manufacturer had lost 7.92% in the past month. In that same time, the Medical sector lost 3.74%, while the S&P 500 gained 0.55%.
Investors will be eagerly watching for the performance of Boston Scientific in its upcoming earnings disclosure. The company's earnings report is set to be unveiled on October 28, 2026. In that report, analysts expect Boston Scientific to post earnings of $0.76 per share. This would mark year-over-year growth of 1.33%. Simultaneously, our latest consensus estimate expects the revenue to be $5.23 billion, showing a 3.25% escalation compared to the year-ago quarter.
Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of $3.25 per share and revenue of $21.22 billion. These totals would mark changes of +6.21% and +5.72%, respectively, from last year.
Investors should also note any recent changes to analyst estimates for Boston Scientific. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 1.3% lower. Boston Scientific is currently sporting a Zacks Rank of #4 (Sell).
Valuation is also important, so investors should note that Boston Scientific has a Forward P/E ratio of 13.28 right now. This expresses a discount compared to the average Forward P/E of 19.67 of its industry.
One should further note that BSX currently holds a PEG ratio of 1.04. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. By the end of yesterday's trading, the Medical - Products industry had an average PEG ratio of 1.71.
The Medical - Products industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 100, positioning it in the top 41% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.
View the Zacks #1 Rank List
Image: Bigstock
Boston Scientific (BSX) Stock Sinks As Market Gains: What You Should Know
Boston Scientific (BSX - Free Report) closed at $42.60 in the latest trading session, marking a -1.46% move from the prior day. The stock fell short of the S&P 500, which registered a gain of 0.73% for the day. Elsewhere, the Dow gained 0.49%, while the tech-heavy Nasdaq added 1.19%.
Coming into today, shares of the medical device manufacturer had lost 7.92% in the past month. In that same time, the Medical sector lost 3.74%, while the S&P 500 gained 0.55%.
Investors will be eagerly watching for the performance of Boston Scientific in its upcoming earnings disclosure. The company's earnings report is set to be unveiled on October 28, 2026. In that report, analysts expect Boston Scientific to post earnings of $0.76 per share. This would mark year-over-year growth of 1.33%. Simultaneously, our latest consensus estimate expects the revenue to be $5.23 billion, showing a 3.25% escalation compared to the year-ago quarter.
Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of $3.25 per share and revenue of $21.22 billion. These totals would mark changes of +6.21% and +5.72%, respectively, from last year.
Investors should also note any recent changes to analyst estimates for Boston Scientific. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 1.3% lower. Boston Scientific is currently sporting a Zacks Rank of #4 (Sell).
Valuation is also important, so investors should note that Boston Scientific has a Forward P/E ratio of 13.28 right now. This expresses a discount compared to the average Forward P/E of 19.67 of its industry.
One should further note that BSX currently holds a PEG ratio of 1.04. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. By the end of yesterday's trading, the Medical - Products industry had an average PEG ratio of 1.71.
The Medical - Products industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 100, positioning it in the top 41% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.